KRAS and lung adenocarcinoma: Romero et al. [32] used the CRISPR/Cas9 system to study the role of Kelch-like ECH-associated protein 1 (KEAP1) in KRAS-mutant NSCLC progression and found that loss of KEAP1 leads to the overactivation of nuclear factor erythroid-2-like 2 (NFE2L2), which encodes the transcription factor NRF2 and promotes KRAS-driven lung adenocarcinoma in mice.